The continued emergence of targeted therapies such as amivantamab and sunvozertinib for EGFR exon 20 insertions or lorlatinib in ALK-positive NSCLC represents a growing arsenal of effective therapeutic options58–60. This evidence concerns the gene EGFR and non-small cell lung carcinoma.